Journal
CANCER INVESTIGATION
Volume 32, Issue 9, Pages 451-457Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/07357907.2014.958234
Keywords
Glioblastoma multiforme; Dendritic cell vaccination; Immunotherapy; Survival
Categories
Ask authors/readers for more resources
Objective: Glioblastoma multiforme (GBM) has a poor prognosis. The purpose of this systematic review and meta-analysis was to analyze the outcomes of clinical trials which compared immunotherapy with conventional therapy for the treatment of malignant gliomas. Methods: PubMed, Cochrane and Google Scholar databases were searched for relevant studies. The 2-year survival rate was used to evaluate effectiveness of immunotherapy. Results: Of 171 studies identified, six comparative trials were included in the systematic review. Immunotherapy was associated with a significantly longer OS and 2-year survival compared to conventional therapy. Conclusion: Immunotherapy may improve the survival of patients with GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available